In fact, the antiproteinuric effects of ACE inhibitors and ARBs plateau at doses exceeding those at which the maximum antihypertensive effect is observed. Emphasis on the results of the above ...

Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) DMX-200 is in a pivotal Phase 3 trial for FSGS, a rare and fatal kidney ...

Though the renal protection provided by antihypertensive doses of ACE inhibitors and ARBs has been extensively studied, the dose response of these agents may be different for renal protection.

Once the ARB dose is stable, patients will be randomized to receive either DMX-200 (120 mg capsule twice daily) or placebo. The single Phase 3 trial in FSGS patients has two interim analysis ...

Once the ARB dose is stable, patients will be randomized to receive either DMX-200 (120 mg capsule twice daily) or placebo. The single Phase 3 trial in FSGS patients has two interim analysis ...

The US FDA has confirmed proteinuria as an acceptable primary endpoint in Dimerix ‘s Phase III ACTION3 trial of DMX-200 for ...

Lorundrostat, a selective aldosterone synthase inhibitor, significantly reduced systolic blood pressure in patients with ...

Following a meeting with the US FDA, clinical-stage biotech Dimerix has confirmed the appropriate primary endpoint for full ...

and 19 patients received their ARB dose one hour before induction of anesthesia. The study found that the patients who received an ARB one hour before anesthesia induction had a significantly ...